Indications for the interleukin inhibitor ‘Dupixent’ is being expanded actively in the field.

According to industry sources, after being approved for rashes, Sanofi’s Dupixent (dupilumab) has further demonstrated efficacy in chronic obstructive pulmonary disease (COPD) and is seeking to expand its indication to the area.

Its indication for itchy rashes has been approved recently in Korea. Specifically, it has been approved for the treatment of adult patients aged 18 years or older with moderate-to-severe prurigo nodularis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Prurigo nodularis is a chr